'Am I My Genes?': Fate, Family And Genetic Testing
By NPR Staff,
National Public Radio
| 02. 27. 2012
Advances in genetic testing have improved the prediction, diagnosis and treatment of disease. But having increased information about your genetic makeup can raise some difficult questions and decisions.
Dr. Robert Klitzman wades through some of those challenges in Am I My Genes?: Confronting Fate and Family Secrets in the Age of Genetic Testing. For the book, Klitzman interviewed 64 people whose genetics indicate they might be at risk for Huntington's disease, breast cancer and other illnesses. These individuals faced a number of big choices: the decision to be tested in the first place, whether to reveal the results to family members and doctors, and how to plan for the future.
"People suddenly had to wrestle: Do I tell my 18-year-old son or daughter or my 17-year-old or my 21-year-old child that he or she therefore also has a 50 percent chance of having this mutation? Do I want to have that shadow their lives as they're just getting going on their independent adult lives?" Klitzman tells NPR's John Donvan.
Scientists have isolated thousands of genetic markers that indicate clear...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...